Literature DB >> 33914240

Double positivity of anti-β2-glycoprotein I domain I and anti-phosphatidylserine/prothrombin antibodies enhances both thrombosis and positivity of anti-ADAMTS13 antibody.

Jiwon Yun1, JaYoon Gu1,2, Hyun Kyung Kim3,4.   

Abstract

Although a few antiphospholipid syndrome (APS) occurs with acquired thrombotic thrombocytopenic purpura (TTP), the relationship between antiphospholipid antibodies (aPL) and anti-ADAMTS13 (anti-a disintegrin and metalloprotease with thrombospondin type 1 motif, member 13) antibody remains uncertain. We investigated the relationship between high-risk thrombotic aPL and anti-ADAMTS13 antibody. Two hundred and thirty-seven patients with positive lupus anticoagulant and/or anticardiolipin antibody were included. Anti-β2GPI (anti-β2-glycoprotein I), anti-β2GPIdI (anti-β2-glycoprotein I domain I), anti-PS/PT (anti-phosphatidylserine and prothrombin), ADAMTS13 activity, and anti-ADAMTS13 antibody were measured. Double positivity of anti-β2GPI and anti-PS/PT increased thrombotic risk more than three-fold and showed increased positivity of anti-ADAMTS13 antibody in comparison with the double negative group. Double positivity of anti-β2GPIdI and anti-PS/PT presented both effects even more. In the linear regression analysis, double positivity of anti-β2GPI and anti-PS/PT independently affected the anti-ADAMTS13 antibody level (β = 1.982, P = 0.042). Our results revealed that double positivity of anti-β2GPI or anti-β2GPIdI and anti-PS/PT increased not only thrombotic risk but also the positivity of anti-ADAMTS13 antibody, especially indicating anti-β2GPIdI showed a higher synergistic effect with anti-PS/PT. We suggest a possible association of anti-ADAMTS13 antibody with a high thrombotic risk of APS. Double positivity of anti-β2GPI (anti-β2-glycoprotein I) and anti-PS/PT (anti-phosphatidylserine and prothrombin) antibodies enhanced not only thrombotic risk but also positivity of anti-ADAMTS13 (anti-a disintegrin and metalloprotease with thrombospondin type 1 motif, member 13) antibody. Furthermore, double positivity of anti-β2GPIdI (anti-β2-glycoprotein I domain I) combined with anti-PS/PT even more elevated both thrombosis and positivity of anti-ADAMTS13 antibody. Double positivity of β2GPI and anti-PS/PT was found as an independently significant contributing factor to anti-ADAMTS13 antibody level. We suggest the association between anti-ADAMTS13 antibody and the pathophysiology of antiphospholipid syndrome, which should be further evaluated.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  ADAMTS13; Antiphospholipid antibodies; Phosphatidylserines; prothrombin; Thrombosis; β2-glycoprotein I

Mesh:

Substances:

Year:  2021        PMID: 33914240     DOI: 10.1007/s11239-021-02406-6

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  9 in total

1.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

2.  Low ADAMTS13 levels are associated with venous thrombosis risk in women.

Authors:  D Llobet; I Tirado; N Vilalta; C Vallvé; A Oliver; M Vázquez-Santiago; J Mateo; J Millón; J Fontcuberta; J C Souto
Journal:  Thromb Res       Date:  2017-07-04       Impact factor: 3.944

3.  Reduced ADAMTS13 activity is associated with thrombotic risk in systemic lupus erythematosus.

Authors:  S Martin-Rodriguez; J C Reverter; D Tàssies; G Espinosa; M Heras; M Pino; G Escolar; M Diaz-Ricart
Journal:  Lupus       Date:  2015-03-29       Impact factor: 2.911

4.  Coexistence of anti-β2-glycoprotein I domain I and anti-phosphatidylserine/prothrombin antibodies suggests strong thrombotic risk.

Authors:  Jee-Soo Lee; JaYoon Gu; Hee Sue Park; Hyun Ju Yoo; Hyun Kyung Kim
Journal:  Clin Chem Lab Med       Date:  2017-05-01       Impact factor: 3.694

5.  The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction.

Authors:  S K Austin; R D Starke; A S Lawrie; H Cohen; S J Machin; I J Mackie
Journal:  Br J Haematol       Date:  2008-03-12       Impact factor: 6.998

6.  Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura.

Authors:  Friedrich Scheiflinger; Paul Knöbl; Bettina Trattner; Barbara Plaimauer; Gabriele Mohr; Michael Dockal; Friedrich Dorner; Manfred Rieger
Journal:  Blood       Date:  2003-07-10       Impact factor: 22.113

7.  Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome.

Authors:  Hui Shi; Hui Zheng; Yu-Feng Yin; Qiong-Yi Hu; Jia-Lin Teng; Yue Sun; Hong-Lei Liu; Xiao-Bing Cheng; Jun-Na Ye; Yu-Tong Su; Xin-Yao Wu; Jin-Feng Zhou; Gary L Norman; Hui-Yun Gong; Xin-Ming Shi; Yi-Bing Peng; Xue-Feng Wang; Cheng-De Yang
Journal:  Clin Chem Lab Med       Date:  2018-03-28       Impact factor: 3.694

8.  Serum ADAMTS-13 Levels as an Indicator of Portal Vein Thrombosis.

Authors:  Tomasz Mikuła; Joanna Kozłowska; Wojciech Stańczak; Mariusz Sapuła; Aleksandra Różyk; Alicja Wiercińska-Drapało
Journal:  Gastroenterol Res Pract       Date:  2018-04-18       Impact factor: 2.260

9.  ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases.

Authors:  Manfred Rieger; Pier Mannuccio Mannucci; Johanna A Kremer Hovinga; Andrea Herzog; Gabi Gerstenbauer; Christian Konetschny; Klaus Zimmermann; Inge Scharrer; Flora Peyvandi; Miriam Galbusera; Giuseppe Remuzzi; Martina Böhm; Barbara Plaimauer; Bernhard Lämmle; Friedrich Scheiflinger
Journal:  Blood       Date:  2005-05-12       Impact factor: 22.113

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.